Wir sind mit live! Mehr erfahren

Collegium Pharmaceutical

COLL

Börsenwert 755 Mio. $

23,19 USD

+0,01

0,04 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

23,19

0,00

0 %

1 Tag

0,04 %

5 Tage

4,74 %

1 Monat

4,51 %

3 Monate

-36,06 %

6 Monate

-29,81 %

Seit Jahresbeginn

-49,07 %

1 Jahr

-30,17 %

5 Jahre

10,22 %

10 Jahre

32,89 %

Profil: Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Mitarbeiter: 423

Gesundheitswesen Arzneimittelhersteller – Spezialpräparate und Generika

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 18,8 %

Neutral 62,5 %

Negativ 18,8 %

Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut

Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. ADHD drugs Jornay PM and AZSTARYS now account for over 30% of 2026 sales, are growing robustly, and enjoy patent protection into the 2030s. Pain franchise decline is staged, with Nucynta facing immediate generic pressure, Belbuca's patent risk centered on an April 2027 trial, and Xtampza protected until 2033.

Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut

Zacks Investment Research

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Zacks Investment Research

New Strong Sell Stocks for October 7th

ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.

New Strong Sell Stocks for October 7th

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, launched Start Talking ADHD, an online resource hub offering practical guides to people living with attention-deficit/hyperactivity disorder (ADHD), and the families who support them.

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:

Collegium to Participate in Upcoming Investor Conferences

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt